Vimarsana
Biggest News Aggregation in the World

Narrative Review News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Narrative Review. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Narrative Review Today - Breaking & Trending Today

Researcher helps advance 'Food is Medicine' concept to reach nutrition security goals - Vimarsana News

Researcher helps advance 'Food is Medicine' concept to reach nutrition security goals

Food is many things. It nourishes our bodies, delights our senses, and gives us something to gather around. Food is also a powerful cultural symbol, reflecting traditions, values, and histories of communities around the world.

Beat Summer Fatigue: Tips to Stay Energized and Cool - Vimarsana News

Beat Summer Fatigue: Tips to Stay Energized and Cool

How can you combat summer fatigue and stay energized? Stay hydrated, eat light meals, and adjust your routine to beat the heat and maintain energy.

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo - Vimarsana News

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label...

Novartis Pharma AG: Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo - Vimarsana News

Novartis Pharma AG: Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical meeting2

Skeptical Science New Research for Week #21 2021 - Vimarsana News

Skeptical Science New Research for Week #21 2021

Open access notables How much storage do we need in a fully electrified future? A critical review of the assumptions on which this question depends, Marsden et al., Energy Research & Social Science: